• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Emergence of aldosterone synthase inhibitors for treatment of difficult to treat hypertension.

作者信息

Park Sungha

机构信息

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

出版信息

Hypertens Res. 2025 Nov 14. doi: 10.1038/s41440-025-02468-6.

DOI:10.1038/s41440-025-02468-6
PMID:41238811
Abstract
摘要

相似文献

1
Emergence of aldosterone synthase inhibitors for treatment of difficult to treat hypertension.醛固酮合酶抑制剂用于治疗难治性高血压的出现。
Hypertens Res. 2025 Nov 14. doi: 10.1038/s41440-025-02468-6.
2
Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease.醛固酮合成酶抑制剂与饮食干预：预防和治疗心血管疾病的联合新方法。
Cureus. 2023 Mar 15;15(3):e36184. doi: 10.7759/cureus.36184. eCollection 2023 Mar.
3
Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.巴克斯洛他汀：一种用于治疗顽固性高血压的新型醛固酮合酶抑制剂。
Curr Probl Cardiol. 2023 Nov;48(11):101918. doi: 10.1016/j.cpcardiol.2023.101918. Epub 2023 Jul 2.
4
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.选择性醛固酮合酶抑制剂巴多司他可显著降低顽固性高血压患者的血压。
Front Endocrinol (Lausanne). 2022 Dec 9;13:1097968. doi: 10.3389/fendo.2022.1097968. eCollection 2022.
5
Breaking down resistance: novel aldosterone synthase inhibitors in the management of resistant hypertension.突破耐药性：新型醛固酮合酶抑制剂在难治性高血压治疗中的应用
J Hypertens. 2025 Aug 1;43(8):1286-1295. doi: 10.1097/HJH.0000000000004055. Epub 2025 May 14.
6
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.评估 Baxdrostat（一种用于治疗高血压的醛固酮合酶抑制剂）的 II 期结果。
Expert Opin Investig Drugs. 2023 Jul-Dec;32(11):985-995. doi: 10.1080/13543784.2023.2276755. Epub 2023 Nov 24.
7
Development of Highly Selective Aldosterone Synthase Inhibitors.高选择性醛固酮合成酶抑制剂的研发
ACS Med Chem Lett. 2025 May 21;16(6):1175-1181. doi: 10.1021/acsmedchemlett.5c00222. eCollection 2025 Jun 12.
8
Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors.难治性高血压的新兴治疗方法：洛伦德司他及相关选择性醛固酮合酶抑制剂综述
Cardiol Rev. 2024 Feb 15. doi: 10.1097/CRD.0000000000000665.
9
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.新型醛固酮合酶抑制剂治疗原发性高血压的疗效：一项随机、双盲、安慰剂和阳性对照 2 期临床试验结果。
Circulation. 2011 Nov 1;124(18):1945-55. doi: 10.1161/CIRCULATIONAHA.111.029892. Epub 2011 Oct 10.
10
Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.醛固酮合成酶抑制剂与原发性高血压的治疗
J Clin Endocrinol Metab. 2023 Jul 14;108(8):e638-e639. doi: 10.1210/clinem/dgad071.

本文引用的文献

1
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.饮用含咖啡因咖啡或戒咖啡以降低心房颤动风险：DECAF随机临床试验
JAMA. 2025 Nov 9. doi: 10.1001/jama.2025.21056.
2
Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.巴多司他对慢性肾脏病合并未控制高血压患者的疗效与安全性：一项随机、双盲、安慰剂对照试验
J Am Soc Nephrol. 2025 Sep 6. doi: 10.1681/ASN.0000000849.
3
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
巴多司他治疗未控制及难治性高血压的疗效与安全性
N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2507109.
4
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24.用于治疗难治性高血压的巴多司他：3期临床试验BaxHTN、BaxAsia和Bax24的原理与设计
Hypertens Res. 2025 Aug 25. doi: 10.1038/s41440-025-02297-7.
5
Resistant hypertension: consensus document from the Korean society of hypertension.难治性高血压：韩国高血压学会共识文件
Clin Hypertens. 2023 Nov 1;29(1):30. doi: 10.1186/s40885-023-00255-4.
6
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.非奈利酮与螺内酯在中重度慢性肾脏病顽固性高血压中的事后比较分析
Clin Kidney J. 2022 Oct 30;16(2):293-302. doi: 10.1093/ckj/sfac234. eCollection 2023 Feb.
7
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.巴多司他治疗顽固性高血压的2期试验。
N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7.
8
Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea.韩国一家三级保健中心原发性醛固酮增多症的患病率及临床特征。
Hypertens Res. 2022 Sep;45(9):1418-1429. doi: 10.1038/s41440-022-00948-7. Epub 2022 Jun 9.
9
Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials.药物引起的男性乳房发育症：随机临床试验的系统评价和荟萃分析。
Arch Ital Urol Androl. 2021 Dec 21;93(4):489-496. doi: 10.4081/aiua.2021.4.489.
10
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.聚磺苯乙烯钠（patiromer）对比安慰剂，以增加耐治疗高血压合并慢性肾脏病（CKD）患者使用螺内酯的可能性（AMBER）：一项 2 期、随机、双盲、安慰剂对照试验。
Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15.